Added by |
ircm doc |
Group name |
EquipeCTCS |
Item Type |
Journal Article |
Title |
Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer |
Creator |
Colombo et al. |
Author |
Pierre-Emmanuel Colombo |
Author |
Christophe Taoum |
Author |
Michel Fabbro |
Author |
Stanislas Quesada |
Author |
Philippe Rouanet |
Author |
Isabelle Ray-Coquard |
Abstract |
Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA breaks and are candidate to receive maintenance treatment with PARP inhibitors. While a wealth of literature exists regarding the therapeutic guidance of patients from a medical standpoint, the influence of the HRD status on the surgical outlook has been comparatively limited. In this review, the clinical and biological features of advanced ovarian cancers with BRCA1/2 mutation and/or HRD status are considered with particular reference to their impact on the surgical management and on the medico-surgical sequence. The modification of the surgical indications according to the results of molecular testing in first-line and recurrent settings are discussed. |
Publication |
Critical Reviews in Oncology/Hematology |
Volume |
202 |
Pages |
104469 |
Date |
2024-10 |
Journal Abbr |
Crit Rev Oncol Hematol |
Language |
eng |
DOI |
10.1016/j.critrevonc.2024.104469 |
ISSN |
1879-0461 |
Library Catalog |
PubMed |
Extra |
PMID: 39111459 |
Tags |
BRCA mutation, BRCA1 Protein, BRCA2 Protein, Carcinoma, Ovarian Epithelial, Disease Management, Female, first, first-last-corresponding, First-line treatement, Homologous Recombination Deficiency (HRD), Humans, Lymphadenectomy, Mutation, Ovarian cancer, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Residual disease, review, Surgery |
Date Added |
2025/01/16 - 11:46:52 |
Date Modified |
2025/01/16 - 11:47:59 |
Notes and Attachments |
PubMed entry (Attachment) |